NIPS

DEVICE2 trials

Sponsors

Hebei Medical University, Medical Genome Company

Conditions

Gastric Cancer Peritoneal Metastaseshigh risk pregnancy non invasive prenatal screening sensitivity specificity high risk pregnancy trisomy

Phase 2

A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10

Not yet recruitingNCT07304258

Hebei Medical UniversityGastric Cancer Peritoneal Metastases

Start: 2025-12-12End: 2027-12-31Target: 30Updated: 2025-12-26

Unknown Phase

Clinical evaluation of MGC-NIPS method for noninvasive prenatal screening

Active, not recruitingTCTR20190708001

Medical Genome Companyhigh risk pregnancy non invasive prenatal screening sensitivity specificity high risk pregnancy trisomy

Start: 2019-07-01Target: 1320Updated: 2026-08-03

Related Papers

HIPEC combined with NIPS and tislelizumab for conversion therapy in gastric cancer with peritoneal metastasis (P0CY1 or PCI ≤10): A prospective, single-arm, phase II study.

Journal of Clinical Oncology2026-05-28